Daniel Morgenstern is a Staff Oncologist at Hospital for Sick Children, Toronto and Assistant Professor at the University of Toronto. He originally qualified in the UK where he was an academic clinical lecturer at UCL Institute of Child Health, trained in drug development at the Royal Marsden Hospital Sutton and was the first Sears Foundation / Garron Cancer Centre Fellow in Neuroblastoma at Hospital for Sick Children. He subsequently worked as a consultant in pediatric oncology at Great Ormond Street Hospital where he was clinical lead for the neuroblastoma and autograft programs, and an active member of the European neuroblastoma consortium SIOPEN.

Dr. Morgenstern moved back to SickKids, Toronto in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs, and co-lead of the neuroblastoma service. Dr Morgenstern’s clinical activities are focussed on neuroblastoma and solid tumor patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in pediatric cancers and the development of precision medicine approaches for pediatric solid tumors. He is a member of the study committee for the current COG trial for relapsed/refractory HR neuroblastoma, an active member of the INRG group and is leading the first clinical trial of the Pediatric Cancer Immunotherapy Trials Network (Ped-CITN).   At the Hospital for Sick Children, he is medical director of the oncology and BMT/cellular therapy clinical trials support unit.